Ista Vitrase sNDA extension
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA's revised action date for Ista's pending sNDA for use of Vitrase (ovine hyaluronidase) as a spreading agent is May 5 following an extension; the original user fee date was Feb. 6 (1Pharmaceutical Approvals Monthly Aug. 1, 2003, In Brief). The extension follows Ista's December amendment containing manufacturing information requested in an April 2003 "approvable" letter. An NDA for vitreous hemorrhage is also pending, with action expected by April 4. Ista recently presented a subset analysis showing greater efficacy in patients with diabetes in the two VH pivotal trials. FDA's Dermatologic & Ophthalmic Drugs Advisory Committee concluded March 17, 2003 that the pivotal data did not demonstrate sufficient efficacy for approval, but agreed that additional subgroup analyses could be used to provide evidence of efficacy...
You may also be interested in...
Ista Vitrase supplement
Ista submits sNDA Aug. 4 for use of its pending ophthalmic solution Vitrase (ovine hyaluronidase) "as a spreading agent to facilitate the dispersion and absorption of other drugs." The firm says it is pursuing the additional indication because of shortages of spreading agents, because no additional studies were needed, and because commercialization efforts could begin while the original NDA for vitreous hemorrhage is reviewed. Vitrase became "approvable" April 3 for treatment of vitreous hemorrhage...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.